Protara Therapeutics Inc. Common Stock (NASDAQ:TARA)

Home >> Stock >> Protara Therapeutics Inc. Common Stock >> Reports

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. Protara Therapeutics Inc., formerly known as ArTara Therapeutics, is based in NEW YORK, United States....

+See More

Blog+More

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization.

Laura Hermes

2019-09-09 20:38:00 Monday ET

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization.

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization. As Federal Reserve Ch

+See More

Harley Davidson plans to move its major production for European customers out of America due to European Union tariff retaliation.

Rose Prince

2018-06-21 10:42:00 Thursday ET

Harley Davidson plans to move its major production for European customers out of America due to European Union tariff retaliation.

Harley Davidson plans to move its major production for European customers out of America due to European Union tariff retaliation. European Union retaliator

+See More

It may be illegal for institutional investors to buy-and-hold large equity stakes in a less competitive industry with high market concentration.

Olivia London

2017-11-27 07:39:00 Monday ET

It may be illegal for institutional investors to buy-and-hold large equity stakes in a less competitive industry with high market concentration.

Is it anti-competitive and illegal for passive indexers and mutual funds to place large stock bets in specific industries with high market concentration? Ha

+See More

President Xi seeks Chinese congressional approval for abolishing his term limits of strongman rule with better trade deals and economic ties.

Jacob Miramar

2018-03-03 11:37:00 Saturday ET

President Xi seeks Chinese congressional approval for abolishing his term limits of strongman rule with better trade deals and economic ties.

President Xi seeks Chinese congressional approval and constitutional amendment for abolishing his term limits of strongman rule with more favorable trade de

+See More

JPMorgan Chase CEO Jamie Dimon sees great potential for 10-year government bond yields to rise to 5%.

Olivia London

2018-08-05 12:34:00 Sunday ET

JPMorgan Chase CEO Jamie Dimon sees great potential for 10-year government bond yields to rise to 5%.

JPMorgan Chase CEO Jamie Dimon sees great potential for 10-year government bond yields to rise to 5% in contrast to the current 3% 10-year Treasury bond yie

+See More

The new antitrust enforcement paradigm

Joseph Corr

2023-10-14 10:32:00 Saturday ET

The new antitrust enforcement paradigm

Jonathan Baker frames the current debate over antitrust merger review and enforcement in America. Jonathan Baker (2019)   The antitrust paradi

+See More